General Information
Novo Diabetes 3839
A 16-week, uncontrolled, single armed, multicentre, treat-to target trial assessing the implications of switching from insulin glargine once daily (OD) to insulin degludec 200 U/ml three times weekly in subjects with type 2 diabetes mellitus currently treated with insulin glargine OD and oral antidiabetic drugs (OADs)
| Protocol | NN1250-3839 |
|---|---|
| Identifier | NN1250-3839 |
| UID | f85be3af-947a-44a7-9e52-fe3e3bd2c666 |
| Status | Done - Archived |
| Phase | 3a |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2010 |
| NCT Number | - |
| Created | 2010-05-21 16:00 |
| Last Updated | 2010-05-21 16:00 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2010-06-01 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2010-12-06 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | - | No | |
| Coordinator | Soler, Daniel | DSoler | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Novo Nordisk |
|---|---|
| Division | Novo Nordisk |
| Team | Novo Nordisk |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
